Farid Mallat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Farid Mallat has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Maroun Aoun
Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
2 shared publications - Albert Riachy
Pulmonary and Critical Care Department, Hôtel Dieu de France University Hospital, Beirut, Lebanon
1 shared publication - Antoine El Kik
Pulmonary and Critical Care Department, Hôtel Dieu de France University Hospital, Beirut, Lebanon
1 shared publication - Boutros Soutou
Dermatology Department, Faculty of Medicine, University Medical Center Hôtel-Dieu de France Hospital, Saint Joseph University of Beirut, Beirut, Lebanon
1 shared publication - Dalia Al Halabi
Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
1 shared publication Elias Al Helou
1 shared publication
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in World Neurosurgery
- Vol. 213
Twist-Drill Evacuation of Chronic Subdural Hematoma: Clinical Correlation with Postoperative Radiological Findings
- 24 July 2026
- Published by Elsevier in World Neurosurgery
- Vol. 213
Open AccessTwist-Drill Evacuation of Chronic Subdural Hematoma: Clinical Correlation with Postoperative Radiological Findings
- Open Access
- 4 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108392
Morpho-clinical insights into moderate-to-severe obstructive sleep apnea
- 4 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108392
Open AccessMorpho-clinical insights into moderate-to-severe obstructive sleep apnea
- Open Access
- 14 January 2025
- Published by MDPI AG in Preprints.org
Effective Intramuscular Vitamin D2 in Patients with Systemic Sclerosis Non-Responding to Oral Supplementation; A Retrospective Observational Case Series
Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.
- 14 January 2025
- Published by MDPI AG in Preprints.org
Open AccessEffective Intramuscular Vitamin D2 in Patients with Systemic Sclerosis Non-Responding to Oral Supplementation; A Retrospective Observational Case Series
Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 2853007
Insights Into the Emerging Entity of HER2‐Low Breast Cancer
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 2853007
Open AccessInsights Into the Emerging Entity of HER2‐Low Breast Cancer
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.
- 20 June 2023
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 46 (4) , 164-167
Botulinum Toxins and Zinc: From Theory to Practice—A Systematic Review
Objective: The aims of this study were to determine whether zinc supplementation affects botulinum toxin's effect and longevity and to establish a transition from the molecular to the clinical aspect. Methods: We conducted a systematic review in which we included all published studies on PubMed and Embase using the combination of the following terms: “zinc” AND (botox OR botulinum OR onabotulinumtoxinA OR abobotulinumtoxinA OR incobotulinumtoxinA). Results: From the 260 yielded articles, 3 randomized control trials and 1 case report were retained. Three of them found a significant improvement with zinc supplementation in the toxin's effect and longevity. This was observed in neurological conditions and cosmetic uses. Conclusions: Zinc supplementation could be an interesting asset in the potentialization of botulinum neurotoxin effect and longevity. Larger clinical trials and objective measurement tools should be used to further defining the role of zinc in maximizing botulinum neurotoxin effect.
- 20 June 2023
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 46 (4) , 164-167
Botulinum Toxins and Zinc: From Theory to Practice—A Systematic Review
Objective: The aims of this study were to determine whether zinc supplementation affects botulinum toxin's effect and longevity and to establish a transition from the molecular to the clinical aspect. Methods: We conducted a systematic review in which we included all published studies on PubMed and Embase using the combination of the following terms: “zinc” AND (botox OR botulinum OR onabotulinumtoxinA OR abobotulinumtoxinA OR incobotulinumtoxinA). Results: From the 260 yielded articles, 3 randomized control trials and 1 case report were retained. Three of them found a significant improvement with zinc supplementation in the toxin's effect and longevity. This was observed in neurological conditions and cosmetic uses. Conclusions: Zinc supplementation could be an interesting asset in the potentialization of botulinum neurotoxin effect and longevity. Larger clinical trials and objective measurement tools should be used to further defining the role of zinc in maximizing botulinum neurotoxin effect.